Half of biotech boards are all-male, worse to come
This article was originally published in Scrip
Executive Summary
Not only is gender bias as prevalent in fledgling biotech companies as it is in big pharma, the problem isn't going to get better any time soon if the pattern of recent appointments continues, a new report says.